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Abstract
In chronic kidney disease both renal insufficiency and chronic inflammation trigger elevated
hepcidin levels, which impairs iron uptake, availability. and erythropoiesis. Here we report
the two first-in-human phase 1 trials of PRS-080#22, a novel, rationally engineered Anticalin
protein that targets and antagonizes hepcidin. A single intravenous infusion of placebo or
PRS-080#22 was administered to 48 healthy volunteers (phase 1a) and 24 patients with
end stage chronic kidney disease (CKD) on hemodialysis (phase 1b) at different doses
(0.08-16mg/kg for the phase 1a study and 2-8mg/kg for the phase 1b study) in successive
dosing cohorts. The primary endpoint for both randomized, double-blind, phase 1 trials was
safety and tolerability. Following treatment, all subjects were evaluable, with none
experiencing dose limiting toxicities. Most adverse events were mild. One serious adverse
event occurred in the phase 1b (CKD patient) study. There were no clinically significant
changes in safety laboratory values or vital signs. PRS-080#22 showed dose-proportional
pharmacokinetics (PK), with a terminal half-life of approximately three days in healthy volun-
teers and 10 to 12 days in CKD patients. Serum hepcidin levels were suppressed in a dose
dependent manner and remained low for up to 48 hours after dosing. PRS-080#22 dose-
dependently mobilized serum iron with increases in both serum iron concentration and
transferrin saturation. No consistent changes were observed with regard to ferritin, reticulo-
cytes, hemoglobin, and reticulocyte hemoglobin. Low titer anti-drug-antibodies were
detected in five healthy volunteers but in none of the CKD patients. PRS-080#22, a novel
Anticalin protein with picomolar affinity for hepcidin, was safe and well-tolerated when
administered to healthy volunteers and CKD patients at all doses tested. The drug exhibited
linear pharmacokinetics, longer half-life in CKD patients in comparison to healthy volunteers
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as well as expected pharmacodynamic effects which hold promise for further clinical
studies.
Introduction
Anemia is a frequent complication of chronic kidney disease (CKD). The incidence and preva-
lence of anemia increases in patients with more advanced stages of CKD, as kidney function
declines [1, 2]. The most common causes are iron deficiency and insufficient erythropoietin
(EPO) production [2]. Consequently, current treatment regimens consist of iron (oral or intra-
venous (IV)), erythropoietin stimulating agents (ESAs), or a combination of both. Adequate
iron stores are essential for achieving maximum benefit from ESAs; therefore, most end-stage
CKD patients also receive IV iron supplementation. However, IV iron may cause infrequent
but severe adverse reactions and concerns about long-term safety have been raised [3,4]. A
clear relationship between iron therapy and hepatic iron overload has been demonstrated by
hepatic MRI [5]. ESA therapy, particularly at high doses, has been associated with an increased
risk of cardiovascular complications and mortality [6]. Finally, a significant number of patients
remain anemic despite combination therapy with ESAs and IV iron. In this light, there is a sig-
nificant need for novel therapeutic approaches to address ESA/iron resistant anemia in CKD
patients.
Hepcidin, a liver-derived 25 amino acid peptide hormone, is a central regulator of iron
homeostasis. Many disorders of iron imbalance can be attributed to aberrant hepcidin produc-
tion [7]. Hepcidin binds to and degrades the iron export channel ferroportin in both the gut
and the plasma membranes of reticuloendothelial cells, thereby inhibiting iron transport. Ele-
vated plasma levels of hepcidin cause iron sequestration in macrophages, which may lead to
functional iron deficiency despite replete iron stores [8]. Hepcidin is frequently elevated in
CKD patients [9–11] and is thought to represent a root cause of the hypoferremia, iron-
restricted erythropoiesis, and refractory anemia in these patients. As hepcidin levels correlate
directly with creatinine levels and inversely with glomerular filtration rate (eGFR), elevated
hepcidin in CKD patients may in part be due to decreased renal clearance [12]. Chronic
inflammation may also contribute to increased levels of hepcidin in CKD [13–15].
In this light neutralizing hepcidin activity could represent a promising approach for the
treatment of functional iron deficiency anemia in CKD patients.
PRS080#022 is a PEGylated (polyethylene glycol bound) Anticalin protein that antagonizes
hepcidin with picomolar affinity. Anticalin proteins are a novel class of small, highly stable
proteins with designed ligand-binding properties derived from the natural human lipocalin
scaffold [16]. Lipocalins are a widespread family of low molecular weight binding proteins that
transport, store, or sequester small biological compounds like vitamins and hormones in many
organisms, including humans [17].
PRS-080#022 showed a benign toxicity profile in preclinical studies, including in non-
human-primates; the results of the toxicity studies did not point to a target organ of toxicity.
In preclinical studies the elimination route was mainly renal.
Further, repeated PRS-080#022 dosing in cynomolgus monkeys potently suppressed hepci-
din resulting in sustained iron mobilization [18]. In this light, hepcidin inhibition by PRS-
080#022 has the potential to ameliorate functional iron deficiency anemia in CKD patients.
Here we are reporting the results of the first two (phase 1a and 1b) clinical trials of PRS-
080#022 in humans.
PRS-080#22, in healthy volunteers and patients with CKD
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Methods
The phase 1a study in healthy volunteers was conducted by the phase 1 unit of Nuvisan
Pharma Services GmbH in Neu-Ulm/Germany and reviewed and approved by the Ethical
Committee (EC) of the Bavarian State Medical Council, Muehlbaurstrasse 16, 81677 Munich
(approval 03 Nov 2014), Germany; the multi-center phase 1b CKD study was performed in 5
clinical centers in Germany and approved by applicable regional independent ethics commit-
tee (IEC) according to German regulations (approval 07 Mar 2016). Both studies were super-
vised by the German Federal Ministry for Drugs and Medical Products (BfArM). Originally
the first study was planned in two stages, the first one to be conducted as single administration,
the second as multiple administrations. After consultations with BfArM the second stage was
cancelled and is currently being performed in CKD patients as separate study. The first part
was conducted as planned and is presented in this manuscript. All subjects gave their signed,
informed consent to participate in the study. Study periods (first subject in–last follow up
visit) were for the healthy volunteer study: December 04, 2014 –June, 8 2015 and for the CKD
study: June 07, 2016 –March 17, 2017. The protocols for these trials are available as supporting
information; S1 and S2 Protocol. Consort flowcharts for both studies are provided as Figs 1
and 2. Both single ascending dose studies were randomized, double-blind and placebo con-
trolled. Both studies are registered on Clintrials.gov (https://clinicaltrials.gov/, NCT02340572
and NCT02754167). As there is no regulatory obligation to publish early phase 1 studies, this
was not considered a priority at the time of the start of the first trial. Registration was done
after recruitment of volunteers had started. The authors however confirm that all related and
following trials have been appropriately registered.
Subjects
For the healthy volunteer study, common inclusion criteria for healthy volunteers were
applied. Additionally, ferritin levels had to be between 10 and 300ng/mL. Iron treatment or
blood transfusions within 90 days prior to treatment, as well as EPO treatment within 1 year,
were prohibited. All screened volunteers met the inclusion and exclusion criteria and were
included in the study.
The main inclusion criteria for the CKD study were: Stage 5 CKD having been on hemodi-
alysis for at least 90 days, stable (less than 30% change) ESA dose for 6 weeks prior to study
medication administration, hemoglobin (Hb) 9.0–12.0 g/dL with no changes greater than 1.5
g/dL over the last 6 weeks prior to study medication administration, ferritin�300 ng/mL,
transferrin saturation (TSAT)�40%, hepcidin 5–75nM. Any iron medication had to be
stopped 7 days before the administration of study medication. Forty patients were screened, of
which 24 were included and treated. Fifteen patients did not meet the inclusion criteria and
one patient withdrew informed consent before treatment.
Trial design and treatment
PRS080#022 was dissolved in 0.9% NaCl solution by an independent pharmacy and adminis-
tered intravenously by slow infusion. For placebo only 0.9% NaCl was provided in identical
vials, labelled in a blinded fashion. In the healthy volunteers study a volume of 250 mL was
given over 2 hours. Six dose groups (0.08, 0.4, 1.2, 4, 8, 16 mg/kg) were assessed in the healthy
volunteer study. Six subjects received active drug and 2 subjects received placebo in each dose
group. Dosing was performed stepwise in sub-groups of 2 subjects each for dose group 1 and
for the following dose groups in one subgroup of 2 and three sub-groups of 3 subjects each.
Drug administration started sequentially between each individual subject with an interval of
150 minutes after start of infusion. Safety data were reviewed after each step of the staggered
PRS-080#22, in healthy volunteers and patients with CKD
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dosing and before dose escalation. The volunteers were closely monitored (confined to the
phase 1 unit for 72 hours), follow up evaluations were performed at 120 hours, 240 hours and
28 days (± 2).
In the CKD study, a volume of 100 mL was given over 1 hour and 3 dose groups (2, 4, 8 mg/
kg) were included. Six subjects received active drug and 2 subjects received placebo in each dose
group. Patients were observed for at least 4 hours after the end of infusion. Follow-up visits were
performed to assess safety, PK and PD at days 1, 2, 3, 5, 7, 14, 21, and 28 after treatment. The deci-
sion to escalate dose (by the dose escalation committee, DEC) was based on a review of safety and
pharmacodynamic data (PD) after the last patient in a cohort had completed day 7.
Safety assessments
Safety assessments were performed on admission to the clinical unit for the HV study and
within the 4 week screening period for the CKD patient study, before dosing, and at scheduled
Fig 1. CONSORT flowchart for study PCS-01-12 in healthy volunteers.
https://doi.org/10.1371/journal.pone.0212023.g001
PRS-080#22, in healthy volunteers and patients with CKD
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intervals after dosing. These assessments included: monitoring for adverse events (as specified
by the study protocols and according to GCP guidelines), vital signs including blood pressure,
pulse rate, respiratory rate and body temperature, 12-lead ECG, local tolerability at injection
site, and clinical safety laboratory tests including biochemistry, hematology, coagulation, and
urinalysis (only the healthy volunteer study) parameters. In addition, blood samples in the
healthy volunteer study were immediately frozen and processed for inflammatory cytokines
(Il-1β, IL-6, IFN-γ, and TNF-α) by a validated multiplex assay (Meso Scale Discovery) before
dosing and at scheduled intervals after dosing.
Pharmacokinetic assessments
Venous blood samples were collected for total and free PRS-080#022 assays. Blood samples
were collected before (t = 0) and at fixed intervals for up to 240 hours after single intravenous
dosing. Concentrations of free and total PRS-080#022 in plasma were assessed using validated
Fig 2. CONSORT flowchart for study PCS-02-15 in CKD patients.
https://doi.org/10.1371/journal.pone.0212023.g002
PRS-080#22, in healthy volunteers and patients with CKD
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enzyme linked immunosorbent assay and electro-chemi-luminescence methods, respectively.
The free PRS-080#022 assay employed capturing via hepcidin and detection via a PRS-
080#022 specific antibody; the total PRS-080#22 assay employed 2 different PRS-080#022 anti-
bodies for capturing and detection, independent of bound hepcidin. The lower limit of detec-
tion was 0.1ng/mL.
PK parameters were derived by non-compartmental methods [19] using programs devel-
oped in SAS version 9.3.
Parameters comprised maximal concentration (Cmax), time of Cmax (tmax), area under the
concentration time curve (AUC) from time 0 to last sample with a quantifiable concentration
(AUC0-t), AUC from 0 to infinity (AUC0-inf), terminal half-life (t1/2), apparent mean residence
time (MRT), total plasma clearance (CL), volume of distribution during the terminal phase
(Vz) and apparent volume of distribution at steady state (Vss).
Based on the single dose pharmacokinetic behavior in CKD patients, simulations of steady-
state conditions using a– 2 compartment model, were performed to assess the risk of drug
accumulation in future studies under repeated dosing conditions.
Pharmacodynamic assessments
Free plasma hepcidin concentrations were measured by weak cation exchange enrichment of
hepcidin followed by matrix-assisted laser desorption/ionization time-of-flight mass spec-
trometry. [20,21] This assay specifically detects free hepcidin which is not bound to PRS-
080#022. Samples were taken at the same time points as the PK samples plus additional mea-
surements at admission and 28 days after dosing.
The following pharmacodynamic variables were also measured before and up to 28 days
after dosing by common methods: iron, transferrin saturation and ferritin, and Hb, reticulo-
cytes and reticulocyte Hb. Blood sampling was done at the same time of the day (before/after
dialysis) except the early timepoints during day 1.
Immunogenicity assessments
Blood samples for the determination of serum concentrations of anti-drug antibodies (ADA)
were taken pre-dose and 28 days after dosing. ADAs were determined by using a bridging
ligand binding assay, which was developed for PRS-080#022 DP and validated [22–24]. The
sensitivity of the test was 12.5 ng/mL. Samples were initially screened at a dilution of 1:100.
Then a confirmative assay was performed and positive samples were further analyzed in a titra-
tion assay.
Statistical methods
As the studies were exploratory in nature, no hypotheses were formulated and no number cal-
culations were performed. All parameters were summarized descriptively by dose level.
Patients were included in consecutive order by the investigators, randomly allocated and
assigned to treatment groups with an interactive voice response system (IVRS). All statistical
analyses were done using SAS version 9.3 (SAS Institute Inc, Cary, NC, USA) on a Windows
XP personal computer.
The PK parameters AUC0-t, AUC0-inf and Cmax of total PRS-080#022 were assessed for
dose-proportionality using the respective linear regression model relating the logarithm of
dose as independent variable to the logarithm of the PK parameters. In order to investigate
dose-proportionality, an estimate for the slope of the regression line with a 95% confidence
interval was presented. A value which was appreciably different from 1 provided evidence for
non-proportionality.
PRS-080#22, in healthy volunteers and patients with CKD
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Results
Differences with regard to age and weight between the dosing groups in both studies were
small and without clinical relevance. CKD patients had to be on hemodialysis for at least 90
days before entering the phase 1b study. Blood transfusions within 2 months of screening were
prohibited. They all followed a dialysis regimen of 3 times a week; different dialysis protocols
were allowed (e.g., overnight dialysis).
The disposition of subjects is provided in Table 1, additional descriptive statistics are pro-
vided in S1 and S2 Tables.
Safety
PRS-080#022 was well tolerated in both studies. There were no serious adverse events (SAEs)
observed in the healthy volunteer study. One SAE was reported in the CKD study. This patient
suffered from worsening of dry gangrene at one of the toes. The illness of diabetic foot syn-
drome was known for 10 years and the patient had previously undergone amputation of a toe
due to this condition. Prior to the study’s initiation the patient had suffered from episodic
deterioration, such that a progression of the disease could be expected. The investigator
assessed this event as not related to study medication but to the underlying disease. However,
the German competent authorities requested to relabel the AE as possibly related as a causal
relationship could not be ruled out.
Apart from infusion-related reactions like flushing and injection site erythema (2 cases in
the healthy volunteers’ study) the related AE’s were unspecific in nature (headache, abdominal
discomfort, decreased exercise tolerance) and did not occur more than once per dose group,
apart from headache (2 cases in the 16mg dose group) (Tables 2 and 3).
In both studies, individual data related to biochemistry, hematology, coagulation and uri-
nalysis parameters showed no clinically relevant changes after administration of PRS-080#022.
There were no effects on vital signs (e.g., heart rate, body temperature, blood pressure,) and
ECG in comparison to placebo in any of the patients.
There were no hypersensitivity responses and no infusion reactions in either study, nor
were there any changes in inflammatory cytokine levels in healthy volunteers.
Local tolerability was excellent: One mild injection site erythema after administration of 4
mg/kg in the HV study was the only local finding (reported as AE, see Table 2).
Pharmacokinetic evaluations
The main PK parameters (mean values and SD) are summarized in Table 4, additional descrip-
tive statistics are provided in S3 and S4 Tables. Time concentration curves for the arithmetic
mean of PRS-080#022 are presented in S1 and S2 Figs.
In both studies AUC’s increased with the dose of study medication. The AUC’s for free
PRS-080#022 were approximately 2-fold higher in the healthy volunteer study, whereas for
Table 1. Disposition of subjects and selected baseline laboratory parameters in healthy volunteers and CKD patients, mean values and [ranges].
Mean BMI Mean Age
(years)
Mean Weight
(kgs)
Gender Creatinine mg/
dl
Albumine g/
dl
Iron
μg/dl
Ferritin ng/
mL
eGFR� mL/
min
Healthy volunteers
(N = 48)
24.5 [20.4–
28.8]
36.1 [18–50] 76.8 [60.1–
90.0]
100% male 0.9 [0.7–1.2] 4.7 [4.2–5.5] 109.7 [39.1–
252.42]
74.2 [14.3–
225.4]
123.1
CKD (N = 18) 26.6 [18.3–
35.5]
55.4 [28–72] 77.1 [50–
107.4]
71% male, 29%
female
8.6 [4.2–14.5] 4.2 [3.6–4.9] 85.5 [29–106] 732.7 [310–
1603]
10.2
�calculated using the Cockroft & Gault Formula based on mean values, therefore a range is not meaningful
https://doi.org/10.1371/journal.pone.0212023.t001
PRS-080#22, in healthy volunteers and patients with CKD
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total PRS-080#022 the AUC’s were higher in the CKD study. Free PRS-080#022 increased
slightly more than dose-proportionally (especially in the lower dose groups), whereas total
PRS-080#022 showed a dose proportional AUC increase. Cmax increased with dose as well,
with very similar results in both studies. Elimination half-life (t ½) ranged from 41–62 hours
for free PRS-080#022 and 73–80 hours for total PRS-080#022 in healthy volunteers. In CKD
patients the elimination half-life was 5–6 times longer, between 218 and 286 hours (9–12
days). For total PRS-080#022 the volume of distribution did not differ between doses, or
between healthy volunteers and end stage CKD patients, for free PRS-080#022volume of distri-
bution was slightly higher for the CKD patients. However, the volume of distribution was very
low in general suggesting no significantly different patterns of distribution between healthy
volunteers and CKD5 patients.
The regression analysis for total PRS-080#022 to evaluate dose proportionality did not
show a deviation from the proportionality assumption (the 95% confidence intervals slopes for
AUC0-t, AUC0-1, and Cmax included the “1”-value.)
The 2-compartmental analysis mainly confirmed the results presented above. Additionally,
the bi-exponential elimination of free PRS-080#022 in each dose group was analyzed, with a
fast first disposal half-life [t1/2(α)] of 6.1 hours (2 mg/kg), 12.5 hours (4 mg/kg), and 16.5 hours
(8 mg/kg). For total PRS-080#022-DP, the t1/2(α) was 9.9 hours (2 mg/kg), 18.3 hours (4 mg/
kg), and 13.9 hours (8 mg/kg). The increase in half-life and AUC of total and free PRS-
080#022 was more pronounced between the 2 mg/kg dose group and both higher dose groups.
Steady-state simulations were performed in order to evaluate the risk for accumulation in
case of multiple administration for future studies. They showed an accumulation factor of
approximately 2.5 and indicate that steady-state of total and free PRS-080#022 will be reached
after approximately 6 weekly infusions of 2, 4, or 8 mg/kg PRS-080#022-DP. The simulation
curve for free PRS-080#022-DP is presented as S3 Fig.
In order to evaluate a potential influence of dialysis on the time concentration curves, an
analysis between the 44 and 48 hour time points (dialysis window at day 2) was performed in
the CKD study. No consistent changes were observed between 44 and 48 hours after adminis-
tration in any of the dose groups.
Fast response Pharmacodynamic Parameters (Iron, TSAT, Ferritin)
In the healthy volunteer study, the two lowest dose groups did not show any response in iron
and TSAT, while in the 4 higher dose groups responses were dependent on the pre-dose hepci-
din levels. Eight subjects did not show any response, all having hepcidin values below the
lower limit of quantification (0,5 nM). Three subjects with hepcidin values below 1 nM showed
Table 2. Adverse events (frequency) in healthy volunteers.
- Placebo
N = 12
0.08mg/kg
N = 6
0.4 mg/kg
N = 6
1.2 mg/kg
N = 6
4 mg/kg N = 6 8 mg/kg N = 6 16 mg/kg
N = 6
Subjects with any
AE
5 (41.7%) 1 (16.7%) 3 (50%) 3 (50%) 3 (50%) 3 (50%) 4 (66%)
Number of AEs 7 1 6 7 5 8 5
Mild AE 6 (86%) 0 5 (83%) 5 (71%) 5 (100%) 5 (63%) 4 (80%)
Moderate AE 1 (14%) 1 (100%) 1 (17%) 2 (29%) 0 3 (38%) 1 (20%)
ADR� 1 (14%) 0 0 0 2 (40%) 2 (25%) 2 (40%)
Kind of ADR Headache na na na Headache, Injection site
erythema
Abdominal discomfort,
Flushing
Headache
�related or possibly related ADR = adverse drug reaction; na = not applicable
https://doi.org/10.1371/journal.pone.0212023.t002
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a weak response, However, those subjects who had higher hepcidin values showed a response
pattern similar to the CKD patients. The dependence of the iron/TSAT response on detectable
hepcidin levels in the healthy volunteers indicated that the drug’s mechanism of action was tar-
get dependent.
In the CKD study, patients’ serum iron concentrations were not balanced at baseline, they
seemed to increase with dose, which is related to the small sample size. Serum iron and TSAT
increased markedly after dosing with PRS-080#022, with peak values at 19 hours post-dose for
the lower dose groups and at 29 hours in the 8mg dose group (Figs 3 and 4). The duration of
Table 3. Adverse events (frequency) in patients with CKD.
- Placebo, N = 6 2 mg/kg, N = 6 4 mg/kg, N = 6 8 mg/kg, N = 6
Subjects with any AE 2 (33.3%) 5 (83.3%) 4 (66.7%) 1 (16.7%)
Number of AEs AE 3 8 10 1
Mild AE 3 (100%) 7 (88%) 10 (100%) 0
Moderate AE 0 1 (13%) 0 1 (100%)
ADR� 0 1 (13%) 2 (20%) 0
Kind of ADR Decreased exercise tolerance Worsening of dry gangrene Abdominal discomfort, Headache
SAE�� na 1 na na
�related or possibly related
�� The ADR “worsening of dry gangrene” was reported as SAE
na = not applicable
https://doi.org/10.1371/journal.pone.0212023.t003
Table 4. Pharmacokinetic parameters in healthy volunteers and CKD patients, mean values and (SD, ranges for tmax).
CKD Study Healthy volunteer Study
Doses 2 mg/kg 4 mg/kg 8 mg/kg 1.2 mg/kg 4 mg/kg 8 mg/kg 16 mg/kg
Free PRS-080#022
AUC 0-t [h
�μg/mL] 484 (39.7) 1713 (48.4) 4 242 (33.0) 748 (68.7) 4 460 (55.0) 10 216 (40.0) 18 497 (42.3)
AUC 0-1 [h
�μg/mL] 466 (37.2) 1 765 (46.3) 4 558 (32.4) 718 (78.9) 4 581 (57.9) 10 185 (47.6) 22 051 (19.4)
C max [μg/mL] 29.0 (25.0) 128.4 (103.3) 159.6 (26.0) 28.7 (20.8) 114.9 (24.7) 202.0 (18.6) 397.2 (21.2)
t max [h] 1.0 (1.0–5.1) 1.0 (1.0–1.0) 1.0 (1.0–5.0) 3.0 (2.0–4.0) 3.0 (2.0–10.0) 2.0 (2.0–6.0) 2.0 (2.0–3.0)
t 1/2 [h] 286.1
b (24.4) 251.6 (28.6) 218.1 b (37.0) 61.6 a (30.6) 44.6 (30.3) 46.5 a (51.5) 41.0 a (28.1)
V ss [L/kg] 0.51
b (47.5) 0.16 (93.2) 0.11 b(42.7) 0.08 a (39.7) 0.04 (30.0) 0.05 a(21.5) 0.05 a (6.4)
Total PRS-080#022
AUC 0-t [h
�μg/mL] 6 912 (28.7) 16 205 (37.3) 33 265 (21.5) 2 259 (7.4) 7 460 (10.1) 14 899 (16.4) 25 253 (18.3)
AUC 0-1 [h
�μg/mL] 8 268 (26.8) 18 651a (45.7) 40 601 (23.2) 2 560 (9.9) 8 263 (11.7) 16 940 (16.5) 27 339 (17.9)
C max [μg/mL] 43.1 (29.8) 211.6 (102.9) 233.3 (49.1) 33.7 (13.0) 119.0 (16.9) 240.9 (23.6) 364.1 (12.2)
t max [h] 1.0 (1.0–20.3) 1.0 (1.0–5.0) 1.0 (1.0–20.8) 2.5 (2.0–4.0) 2.5 (2.0–10.0) 3.0 (3.0–10.0) 3.0 (2.0–4.0)
t 1/2 [h] 259.1 (21.8) 237.4
a (15.8) 270.2 (21.6) 79.7 (13.1) 72.6 (12.7) 79.2 (11.4) 79.5 (15.2)
V ss [L/kg] 0.09 (32.5) 0.07
a (60.6) 0.07 (25.5) 0.05 (8.4) 0.05 (11.8) 0.05 (18.1) 0.06 (22.4)
For the healthy volunteer study the two lowest dose groups (0.04 and 0.08) are not included. Geometric mean and coefficient of variation in percent are presented.
except for tmax for which median and range are presented. N = 6 for each treatment group if not indicated otherwise.
a N = 4.
b N = 5.
AUC0-t = area under the concentration time curve, time 0 to last quantifiable sample; AUC0-1 = area under the concentration time curve, time 0 extrapolated to
infinity; Cmax = measured maximum concentration; N = number of patients; tmax = time of observed maximum concentration; t1/2 = terminal half-life, Vss = volume of
distribution at steady state.
https://doi.org/10.1371/journal.pone.0212023.t004
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the effect was also dose dependent and lasted until 72 hours post PRS-080 administration in
the highest dose group. In this group a transient decrease below the mean baseline value was
observed at Day 7 (Fig 1). Iron and TSAT values are reported in S5 Table.
There were no consistent dose-related post-dose changes for ferritin in either of the two
studies (S6 Table)
Hepcidin (free) analysis
Hepcidin plasma levels showed some variation between screening and day 1 (time 0) with a
decline observed in the CKD patients. As expected, the CKD5 patients had higher baseline
hepcidin values compared to the healthy volunteers. Following dosing with PRS-080-#022 in
both studies, free hepcidin plasma concentrations decreased rapidly and remained suppressed
in a dose-dependent fashion. A subsequent dose related elevation (rebound) of hepcidin levels
above their initial baseline was then observed, persisting beyond the return of iron levels to
baseline and then gradually declining also in a dose dependent fashion. (Table 5, S4 and S5
Figs, S7 and S8 Tables). The magnitude and duration of the hepcidin elevation were greater in
the CKD patients than in the healthy volunteers (Table 5).
Slow response Pharmacodynamic Parameters (ret, Hb, retHb)
Reticulocyte count as well as reticulocyte and erythrocyte hemoglobin did not appear to be
affected by single administration of PRS-080#022 in both trials (S8 Table).
Immunogenicity (development of ADA)
In the HV study 12 samples were identified (screening assay) and confirmed as potentially pos-
itive for ADA, they were therefore analyzed in a titration assay. Five (Day 28) samples were
shown positive for anti-PRS-080 antibodies with titers of 1:400 (n = 4, one subject in the 4mg/
kg, one in the 8 and 2 in the 16mg/kg dose groups) to 1:1600 (n = 1 in the 8mg/kg dose group).
Fig 3. Time concentration curve for iron in CKD patients.
https://doi.org/10.1371/journal.pone.0212023.g003
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In the CKD study the assay for anti-PRS-080#22 specific antibodies did not show a positive
result in any of the dose groups.
Discussion and conclusion
Elevated levels of hepcidin, often related to inflammation, are considered to have a major
causal role in CKD anemia, as hepcidin suppresses both iron uptake and availability, and
hence, erythropoiesis. In epidemiologic studies hepcidin levels correlate with renal anemia
[25], and hepcidin knockout mice are protected from renal anemia [26]. Therefore, direct hep-
cidin antagonism may represent a potentially effective therapeutic approach to ameliorating
renal anemia and its concurrent morbidities. Here we have presented first-in-human data with
the novel and highly selective hepcidin antagonist PRS-080#022, demonstrating safety, phar-
macokinetics, and pharmacodynamics of this novel compound.
In two single ascending dose trials, IV PRS-080#022 administrations were well tolerated up
to the highest tested dose of 16 mg/kg in healthy volunteers (HV) and up to the highest tested
dose of 8 mg/kg in end-stage CKD patients undergoing hemodialysis. Most AEs were mild
and there was only one SAE (worsening of dry gangrene in a patient with a long history of dia-
betic foot syndrome, which was considered possibly related) reported in the CKD study. There
were no clinically significant changes in normal laboratory values including liver transami-
nases. Local tolerance was excellent, with no infusion related reactions reported. Inflammatory
cytokines, which were only assessed in the HV study, remained unaffected.
PRS-080#022 also mediated the expected pharmacodynamic effects of dose-dependently
mobilizing serum iron with increases in both serum iron concentration and TSAT. This sug-
gests that the mobilized iron was almost entirely transferrin bound and therefore highly func-
tional, which favorably differentiates this therapeutic approach from IV iron administration.
Serum ferritin levels were largely unaffected by the treatment, and as ferritin is an acute
phase protein and plays different roles apart from iron storage and transport [27] it is likely
that the characteristics of subject populations have more impact on ferritin changes than the
Fig 4. Time concentration curve for TSAT in CKD patients.
https://doi.org/10.1371/journal.pone.0212023.g004
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hepcidin antagonism. Nevertheless, the treatment with PRS-080#022 did not deplete body
iron stores.
In our studies, no consistent dose-related changes in the slow response parameters Hb, Ret,
and RetHb were shown after a single administration of PRS-080#022; a further multi-dose
study is in progress to show whether repeated administration can sustain enhanced iron mobi-
lization sufficiently to generate new red blood cells and ameliorate anemia.
The observations that AUCs for free PRS-080#022 Anticalin protein were considerably
higher in the healthy volunteer study and that free PRS-080#022 increased slightly more than
dose-proportionally (especially in the lower dose groups), whereas total PRS-080#022 showed
a more dose proportional increase in AUC’s, could be explained by the low levels of hepcidin
in the healthy volunteers. It can be assumed that the initial phase represents a protein binding
process which is not yet saturated with the lowest doses of 1.2 and 2 mg/kg; this process
becomes more saturated with increasing doses. From a safety perspective this finding is quite
relevant because it contributes to the safety profile of the compound; i.e. with higher doses the
pharmacokinetics become more linear, which is supported by the results of the regression
analysis for total PRS-080#022. This analysis did not show a deviation from the proportionality
assumption for AUC0-t, AUC0-1, and Cmax. However, it has to be noted that the small sample
size does not allow for definitive conclusions. Based on preclinical animal data it is known that
the main elimination route of PRS-080 is via the kidneys [18]; therefore, the difference in elim-
ination half-life between healthy volunteers (approx.3 days) and patients with end stage renal
disease on hemodialysis (approx. 10–12 days) would be expected. The simulations based on
the 2-compartmental PK evaluation show an accumulation factor of 2.5, with steady state
reached after 5–6 doses. Therefore 5 administrations of PRS-080#22-DP given at weekly inter-
vals in a multiple dose study should not exceed the plasma concentrations of total and free
PRS-080#022-DP measured after a single administration of 16 mg/kg in healthy volunteers.
Hepcidin plasma levels showed some variation at baseline, especially in the CKD study
where there was a decline between Screening and Day 1 (pre-dose). Hepcidin is known to fol-
low a diurnal rhythm [28,29], but the CKD patients were treated and evaluated following their
regular dialysis scheme (usually at the same time of the day). The protocol however required
that iron administration be stopped one week before treatment, which could have had an influ-
ence on the treatment day 1 hepcidin values.
Table 5. Free hepcidin, mean values (SD) over time in healthy volunteers and CKD patients.
Hepcidin nM (SD) CKD Study Healthy volunteer Study
2mg/kg N = 6 4mg/kg N = 6 8mg/kg N = 6 1,2mg/kg N = 6 4mg/kg N = 6 8mg/kg N = 6 16mg/kg N = 6
Screening 18.1 (7.7) 22.1 (11.8) 30.7 (9.2) 1.9 (3.7) 1.7 (2.0) 0.8 (1.3) 2.6 (3.8)
0 h 7.4 (8.5) 14.4 17.3) 21.1 (4.5) 2.1 (2.3) 2.3 (2.2) 1.1 (1.4) 6.1 (12.1)
1 h 3.1 (6.2) 0.8 (0.9) 1.1 (0.7) 0.3 (0) 0.3 (0) 0.3 (0) 0.7 (1.0)
5/6 h� 9.3 (20.6) 1.6 2.3) 1.6 (0.6) 0.3 (0) 0.34 (0.3) 0.5 0.3) 1.1 (1.3)
18/19 h� 50.1 (31.6) 14.0 (18.5) 12.1 (3.1) 0.8 (0.7) 1.1 0.9) 1.1 (1.0) 2.6 (2.4)
44/48 h� 42.4 (7.3) 75.0 (45.2) 62.33 (45.7) 10.0 (12.0) 2.5 (2.6) 2.3 (2.6) 6.7 (12.5)
72 h 48.0 (22.2) 74.8 (40.3) 123.8 (52.8) 7.8 (8.4) 19.8 (29.1) 28.3 (66.0) 48.2 (111.6)
5 d /120h 44.25 (30.8) 69.1 (32.6) 124.7 (32.8) 5.8 (5.2) 8.2 (10.8) 28.9 (41.4) 33.5 (73.2)
10 d/240h 2.4 (2.2) 5.2 (5.0) 21.1 (23.1) 38.5 (30.6)
14 d/336h 28.3 (13.2) 34.6 (10.5) 79.9 (23.1)
28 d/672h 26.5 (20.7) 27.1 (13.7) 47.5 (11.5) 2.0 (3.8) 2.2 (2.0) 6.6 (10.8) 4.8 (2.9)
�In CKD patients, Iron and TSAT were assessed at 5, 19 and 44 hours, in healthy volunteers at 6, 18 and 48 hours
https://doi.org/10.1371/journal.pone.0212023.t005
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The dose related rebound effect of hepcidin plasma concentrations in both studies followed
as expected the increase of iron and TSAT. This has also been observed with other hepcidin
antagonists such as Lexaptepid and the monoclonal antibody LY2787106 [30,31]. It is known
that hepcidin levels are physiologically increased by a homeostatic feedback loop in response
to elevated plasma iron concentrations and cellular iron stores [32,33]. Chronic inflammation,
which is often present in patients with CKD [17–19], may contribute to hepcidin induction in
the CKD patients as the rebound was prolonged relative to the healthy volunteers. It remains
to be determined in further clinical trials whether this rebound effect can be suppressed by
repeated administrations of PRS-080#022.
Anti-drug-antibodies were assessed before treatment and at day 28, as preclinical studies
have shown that ADA to PRS-080#22 do not develop before day 21. In the healthy volunteer
study ADA were detected in 5 of 36 subjects (14%), which were considered unlikely to inter-
fere with the hepcidin neutralizing activity of the drug. In the healthy volunteer study ADA
were detected in 5 of 36 subjects (14%), which were low titer and considered unlikely to inter-
fere with the hepcidin neutralizing activity of the drug. The ADA rate observed for monoclonal
antibodies has been reported to range between 0 and 12% for fully human products [34] and
the study with LY2787106 showed an ADA rate of 24% [31]. The incidence of ADA is depen-
dent on the immune status of the subject and expected to be higher in healthy volunteers and
immuno-competent patients compared to patients with a compromised immune system [35].
The test for Anti-PRS-080#22 specific antibodies in the CKD study did not show a positive
result in any of the dose groups, potentially due to alterations in the immune system in end
stage renal disease, as uremia is associated with a state of immune dysfunction [36]. Therefore,
the immunogenic potential of PRS-080#022 in CKD patients appears to be low.
In summary, the excellent safety profile and the confirmed activity of PRS-080#022 on iron
metabolism in anemic, dialysis dependent, end-stage CKD patients warrant further investiga-
tion of PRS-080#022 in a multiple dosing regimen to explore potential amelioration of anemia
in these patients. A multiple-ascending dose study in dialysis dependent CKD5 patients is cur-
rently underway.
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